ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1993

Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
Abstract Number: 0818

Risk of Cardiovascular Events is Higher in Pregabalin Users Versus Duloxetine: A Cohort Study Among Veterans with Chronic Musculoskeletal Pain
Abstract Number: 0724

Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data
Abstract Number: 0168

Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
Abstract Number: 2658

Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Abstract Number: 1183

Risk of Inflammatory Bowel Disease in Psoriatic Arthritis Patients Treated with IL-17 Inhibitors
Abstract Number: 0837

Risk of New Proteinuria in Next Ten Years in SLE
Abstract Number: 1656

Risk of Serious Infection associated with non-TNF biologic initiation after Anti-TNF Use in Older Adults with Rheumatoid Arthritis
Abstract Number: 1747

Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
Abstract Number: 0884

Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Abstract Number: 2118

Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Abstract Number: 2448

Rituximab as the first line treatment in newly diagnosed systemic lupus erythematosus
Abstract Number: 1093

Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Abstract Number: 0135

Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Abstract Number: 2524

Rituximab in the Treatment of Susac Syndrome: Single Center Descriptive Study with a Large Susac Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].